Cancer: Looking outside the genome

Nature Reviews Molecular Cell Biology

Volumn 1, Issue 1, 2000, Pages 76-79

  Folkman, Judah ^a   Hahnfeldt, Philip ^a   Hlatky, Lynn ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT;

ANIMAL; ARTICLE; CYTOLOGY; GENETICS; GENOME; HUMAN; METABOLISM; MUTATION; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PATHOPHYSIOLOGY; VASCULAR ENDOTHELIUM;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; ENDOTHELIUM, VASCULAR; GENOME; GENOME, HUMAN; HUMANS; MUTATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0034303726     PISSN: 14710072     EISSN: None     Source Type: Journal    
DOI: 10.1038/35036100     Document Type: Review

References (30)

1. Zhang, L. et al. Gene expression profiles in normal and cancer cells. Science 276, 1268-1272 (1997).
2. Baylin, S. B. & Herman, J. G. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 16, 168-174 (2000).
3. Moinfar, F. et al. Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: Implications for tumorigenesis. Cancer Res. 60, 2562-2566 (2000).
4. Bissell, M. J. et al. Tissue structure, nuclear organization, and gene expression in normal and malignant breast. Cancer Res. 59, S1757-S1763 (1999).
5. Stoler, D. L. et al. The onset and extent of genomic instability in sporadic colorectal tumor progression. Proc. Natl Acad. Sci. USA 96, 15121-15126 (1999).
6. Strohman, R. C. The coming Kuhnian revolution in biology. Nature Biotechol. 15, 194-200 (1997).
7. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70 (2000).
8. Nurse, P. Reductionism: The ends of understanding. Nature 387, 657 (1997).
9. Steeg, P. S. & Abrams, J. S. Cancer prognostics: past, present and p27. Nature Med. 3, 152-154 (1997).
10. Szallasi, Z. Bioinformatics: Gene expression patterns and cancer. Nature Biotechol. 16, 1292-1293 (1998).
11. Howard, K. The bioinformatics gold. Sci. Am. July, 58-63 (2000).
12. Huang, S. & Ingber, D.E. The structural and mechanical complexity of cell-growth control. Nature Cell Biol. 1, E131-E138 (1999).
13. Loeb, L. A. Many mutations in cancers. Cancer Surveys 28, 329-342 (1996).
14. Cahill, D. P., Kinzler, K. W., Vogelstein, B. & Lengauer, C. Genetic instability and darwinian selection in tumours. Trends Cell Biol. 9, M57-M60 (1999).
15. Kinzler, K. W. & Vogelstein, B. Lessons from hereditary colorectal cancer. Cell 87, 159-170 (1996).
16. Hahnfeldt, P., Panigrahy, D., Folkman, J. & Hlatky, L. Tumor development under angiogenic signaling: A dynamical theory of tumor growth, treatment response and post-vascular dormancy. Cancer Res. 59, 4770-4775 (1999).
17. Perez-Atayde, A. R. et al. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am. J. Pathol. 150, 815-821 (1997).
18. Hanahan, D. & Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353-364 (1996).
19. Good, D. J. et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc. Natl Acad. Sci. USA 87, 6624-6628 (1990).
20. Browder, T. et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60, 1878-1886 (2000).
21. Klement, G. et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105, R15-R24 (2000).
22. Folkman, J. Is tissue mass regulated by vascular endothelial cells? Prostate as the first evidence. Endocrinology 139, 441-442 (1998).
23. Feinstein, A. R. The santayana syndrome II: Problems in reasoning and learning about error. Perspect. Biol. Med. 41, 73-85 (1997).
24. Sachs, L. The control of growth and differentiation in normal and leukemic blood cells. The 1989 Alfred P. Sloan Prize of the General Motors Cancer Research Foundation. Cancer 65, 2196-2206 (1990).
25. Folkman, J. in Accomplishments in Cancer Research (eds Wells, S. A. Jr & Sharp, P. A.) 32-44 (J. B. Lippincott Williams and Wilkins, Pennsylvania 1998).
26. Perletti, G. et al. Antitumor activity of endostatin against carcinogen-induced rat primary mammary tumors. Cancer Res. 60, 1793-1796 (2000).
27. Boehm, T., Folkman, J., Browder, T. & O'Reilly, M. S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390, 404-407 (1997).
28. Kerbel, R. S. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anticancer therapeutic agents. BioEssays 13, 31-36 (1991).
29. Streit, M. et al. Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis. Proc. NatlAcad. Sci. USA 96, 14888-14893 (1999).
30. St Croix, B. et al. Genes expressed in human tumor endothelium. Science 289, 1197-1202 (2000).